Reference
Hu S, et al. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus. Applied Health Economics and Health Policy : 12 Aug 2020. Available from: URL: https://doi.org/10.1007/s40258-020-00603-7
Rights and permissions
About this article
Cite this article
Dapagliflozin as add-on to metformin may reduce T2DM burden in China. PharmacoEcon Outcomes News 860, 15 (2020). https://doi.org/10.1007/s40274-020-7061-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7061-5